PMID- 26241950
OWN - NLM
STAT- MEDLINE
DCOM- 20160606
LR  - 20150908
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 33
IP  - 38
DP  - 2015 Sep 11
TI  - Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected 
      children.
PG  - 4790-7
LID - S0264-410X(15)01060-9 [pii]
LID - 10.1016/j.vaccine.2015.07.082 [doi]
AB  - OBJECTIVES: HIV-infected children have poor responses to inactivated influenza 
      vaccines. Live vaccines (LAIVs) are highly efficacious in children, but they are 
      not used in HIV-infected children du e to limited information. We investigated 
      the safety, immunogenicity and viral shedding of LAIV4 in HIV-infected compared 
      with uninfected children. DESIGN: Forty-six HIV-infected and 56 uninfected 
      children 2 to 25 years old, who had been previously vaccinated against influenza, 
      consented to receive a single dose of LAIV4. All grade adverse events (AEs) were 
      recorded in the first month post-vaccination and serious AEs (SAEs) throughout 
      the influenza season. Nasopharyngeal swabs for influenza PCR and IgA ELISA and 
      blood for hemagglutination inhibition antibody (HAI) measurements were collected 
      at entry, 2-5, 7-10 and 21-28 days post-vaccination. RESULTS: The HIV-infected 
      subjects had median CD4+ cells of 649 cells/muL and plasma HIV RNA of 20 
      copies/mL. AEs were similar in the two groups. There were no vaccine-related 
      SAEs. Shedding of >/=1 vaccine virus was detected in 67% HIV-infected and 50% 
      uninfected participants (p=0.14). HAI titers did not appreciably change, but 
      mucosal IgA antibodies significantly increased post-vaccination in both groups. 
      High baseline HAI and IgA antibody concentrations were associated with decreased 
      viral shedding in controls, but not in HIV-infected subjects. Similar proportions 
      of HIV-infected vaccinees and controls reported influenza-like illnesses (12% and 
      6%) throughout the season. CONCLUSIONS: LAIV4 was equally safe and immunogenic 
      and caused similar viral shedding in HIV-infected and uninfected children. A 
      correlate of protection against vaccine viral shedding was not identified in 
      HIV-infected participants, although both circulating and mucosal antibodies 
      correlated with protection in controls.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Curtis, Donna
AU  - Curtis D
AD  - University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, 
      USA.
FAU - Ning, Mariangeli F
AU  - Ning MF
AD  - University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, 
      USA.
FAU - Armon, Carl
AU  - Armon C
AD  - Children's Hospital Colorado, 13123 E 16th Avenue, B055, Aurora, CO 80045, USA.
FAU - Li, Shaobing
AU  - Li S
AD  - University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, 
      USA.
FAU - Weinberg, Adriana
AU  - Weinberg A
AD  - University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, 
      USA. Electronic address: Adriana.Weinberg@ucdenver.edu.
LA  - eng
GR  - UL1 TR001082/TR/NCATS NIH HHS/United States
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150801
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Immunoglobulin A)
RN  - 0 (Influenza Vaccines)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/pathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HIV Infections/complications/*immunology
MH  - Hemagglutination Inhibition Tests
MH  - Humans
MH  - Immunoglobulin A/analysis
MH  - Influenza Vaccines/administration & dosage/*adverse effects/*immunology
MH  - Influenza, Human/*prevention & control
MH  - Male
MH  - Nasopharynx/virology
MH  - Orthomyxoviridae/*isolation & purification
MH  - Polymerase Chain Reaction
MH  - Vaccines, Attenuated/administration & dosage/adverse effects/immunology
MH  - *Virus Shedding
MH  - Young Adult
OTO - NOTNLM
OT  - Children
OT  - HIV
OT  - Immunogenicity
OT  - Influenza infection
OT  - Influenza vaccine
OT  - LAIV4
OT  - Safety
EDAT- 2015/08/05 06:00
MHDA- 2016/06/09 06:00
CRDT- 2015/08/05 06:00
PHST- 2015/03/03 00:00 [received]
PHST- 2015/07/25 00:00 [accepted]
PHST- 2015/08/05 06:00 [entrez]
PHST- 2015/08/05 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - S0264-410X(15)01060-9 [pii]
AID - 10.1016/j.vaccine.2015.07.082 [doi]
PST - ppublish
SO  - Vaccine. 2015 Sep 11;33(38):4790-7. doi: 10.1016/j.vaccine.2015.07.082. Epub 2015 
      Aug 1.